Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.

Candel Therapeutics Grants Inducement Stock Options to New General Counsel

Candel Therapeutics, Inc. announced the grant of stock options to Maria Ostrovsky in connection with her appointment as the company's General Counsel.

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics, Inc. granted stock options to four new employees as an inducement for their employment.

Candel Therapeutics Announces Late-Breaking Abstract Acceptance for SITC 2026 Annual Meeting

Candel Therapeutics will present longitudinal immune-profiling data from its phase 2 PrTK05 clinical trial of aglatimagene besadenovec in localized prostate cancer at the SITC 2026 Annual Meeting.

Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting

Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer

Candel Therapeutics announced that its phase 2 PrTK05 clinical trial data for aglatimagene besadenovec in localized prostate cancer has been accepted for poster presentation at the SITC 41st Annual Meeting in November 2026. The presentation will feature longitudinal immune-profiling, biodistribution, and viral shedding data from the trial combining aglatimagene with valacyclovir and radiation therapy.

Candel Therapeutics to Present at November Investor Conferences

Candel Therapeutics, Inc. announced that it will participate in upcoming investor conferences scheduled for November 2026.